Tolcapone is under clinical development by Corino Therapeutics and currently in Phase II for Familial Amyloid Cardiomyopathy. According to GlobalData, Phase II drugs for Familial Amyloid Cardiomyopathy have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tolcapone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tolcapone overview

Tolcapone (CRX-1008) is under development for the prevention and treatment of transthyretin amyloidosis (ATTR), ATTR-cardiomyopathy (familial amyloid cardiomyopathy), hATTR-Polyneuropathy (hereditary/familial amyloid neuropathies), and hATTR-Leptomeningeal. The drug candidate is administered orally and is a repurposed drug. The drug candidate targets transthyretin. It is developed based on the in silico ligand-based virtual screening repositioning technology.

Corino Therapeutics overview

Corino Therapeutics ( Corino) is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products for the treatment of a variety of human diseases, particularly orphan indications. Corino is headquartered in the US.

For a complete picture of Tolcapone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.